チロシンキナーゼ阻害剤の世界市場レポート 2024年

チロシンキナーゼ阻害剤の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.5%の年間複合成長率（CAGR）で814億1,000万米ドルに成長すると予想されています。予測期間で予想される成長は、医療への投資の増加、バイオマーカー主導療法の出現、ドラッグデリバリーの革新、精密医療パラダイム、と小児腫瘍学への注目の高まりに起因すると考えられます。予測期間中に予想される顕著な動向には、耐性を軽減する戦略、中枢神経系（CNS）浸透性のチロシンキナーゼ阻害剤（TKI）の開発、腫瘍学を超えた応用、モニタリングのためのリキッドバイオプシーの使用、と医療経済の考慮が含まれます。

がん罹患率の予想される増加は、将来のチロシンキナーゼ阻害剤市場の成長を促進すると予想されます。がんは、制御されない細胞増殖を特徴とする多様な疾患群であり、異常な細胞が増殖し、隣接する組織に侵入し、他の器官に転移する可能性があるため、重大な健康上の課題を引き起こしています。 チロシンキナーゼ阻害剤は、特定のチロシンキナーゼをブロックすることで標的療法において重要な役割を果たし、それによってがん細胞の増殖を阻害します。 2023年 1月の時点で、米国がん協会は、がん症例数が2021年の189万8,160人から2023年には195万8,310人に増加し、3.16%の増加を報告しました。このがん症例の急増は、チロシンキナーゼ阻害剤市場の成長を促進する重要な推進力です。

医療支出の増加も、チロシンキナーゼ阻害剤市場の成長を促進するもう1つの要因です。特定の地域、国、または組織内の医療セクターに割り当てられた財源を含む医療支出は、チロシンキナーゼ阻害剤などの標的療法の開発と利用を支援する上で重要な役割を果たします。 2023年 3月、米国医師会は、米国の医療支出が2.7%増加し、2021年には4兆3,000億米ドル、つまり一人当たり1万2,914ドルに達すると報告しました。この医療支出の増加傾向は、チロシンキナーゼ阻害剤市場の成長に大きく貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のチロシンキナーゼ阻害剤市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のチロシンキナーゼ阻害剤の市場規模実績と成長、2018～2023年
• 世界のチロシンキナーゼ阻害剤市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のチロシンキナーゼ阻害剤市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• BCR-ABLチロシンキナーゼ阻害剤
• 上皮成長因子受容体（EGFR）チロシンキナーゼ阻害剤
• 血管内皮増殖因子受容体（VEGFR）チロシンキナーゼ阻害剤
• その他
• 世界のチロシンキナーゼ阻害剤市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 独立系薬局
• オンライン薬局
• 世界のチロシンキナーゼ阻害剤市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 慢性骨髄性白血病（CML）
• 肺がん
• 乳がん
• 腎細胞がん
• その他

第7章 地域と国の分析

• 世界のチロシンキナーゼ阻害剤市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のチロシンキナーゼ阻害剤市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• チロシンキナーゼ阻害剤市場の競合情勢
• チロシンキナーゼ阻害剤市場企業プロファイル
  • Pfizer Inc.
  • Johnson And Johnson Private Limited.
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bayer AG

第31章 その他の大手と革新的な企業

• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca Plc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd
• Incyte Corporation
• Dr. Reddy's Laboratories Ltd.
• Exelixis Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Tyrosine kinase inhibitors (TKI) constitute a class of pharmaceuticals designed to impede multiple pathways through which protein kinases signal the transduction pathway's function. This targeted therapy is employed to selectively target and eliminate specific cancer cell types while preserving healthy cells.

The primary categories of tyrosine kinase inhibitors include BCR-ABL tyrosine kinase inhibitors, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, and others. BCR-ABL tyrosine kinase inhibitors specifically target the enzyme inhibiting BCR-ABL tyrosine kinases, crucial in the pathogenesis of chronic myelogenous leukemia (CML), serving as a first-line therapy for patients with CML. These inhibitors are distributed through various channels such as hospital pharmacies, independent pharmacies, and online pharmacies, and are applied in the treatment of conditions such as chronic myeloid leukemia (CML), lung cancer, breast cancer, renal cell cancer, and others.

The tyrosine kinase inhibitors market research report is one of a series of new reports from The Business Research Company that provides tyrosine kinase inhibitors market statistics, including tyrosine kinase inhibitors industry global market size, regional shares, competitors with a tyrosine kinase inhibitors market share, detailed tyrosine kinase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the tyrosine kinase inhibitors industry. This tyrosine kinase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tyrosine kinase inhibitors market size has grown strongly in recent years. It will grow from $53.72 billion in 2023 to $58.69 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The expansion observed in the historical period can be attributed to the discovery of tyrosine kinases, advancements in the understanding of cancer signaling pathways, the approval of imatinib (Gleevec), the clinical success of early tyrosine kinase inhibitors (TKIs), and investments in research and development.

The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $81.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period can be attributed to increasing investments in healthcare, the emergence of biomarker-driven therapies, innovations in drug delivery, the precision medicine paradigm, and a heightened focus on pediatric oncology. Prominent trends expected during the forecast period encompass strategies to mitigate resistance, the development of central nervous system (CNS)-penetrant tyrosine kinase inhibitors (TKIs), applications beyond oncology, the use of liquid biopsies for monitoring, and considerations of health economics.

The anticipated rise in cancer prevalence is set to drive the growth of the tyrosine kinase inhibitors market in the future. Cancer, a diverse group of diseases characterized by uncontrolled cell growth, poses a significant health challenge as abnormal cells proliferate, invade neighboring tissues, and potentially spread to other organs. Tyrosine kinase inhibitors play a crucial role in targeted therapy by blocking specific tyrosine kinases, thereby inhibiting the growth of cancer cells. As of January 2023, the American Cancer Society reported an increase in cancer cases from 1,898,160 in 2021 to 1,958,310 in 2023, representing a growth of 3.16%. This surge in cancer cases is a key driver fueling the growth of the tyrosine kinase inhibitors market.

The upswing in healthcare spending is another factor propelling the growth of the tyrosine kinase inhibitors market. Healthcare spending, encompassing the financial resources allocated to the healthcare sector within a specific region, country, or organization, plays a crucial role in supporting the development and utilization of targeted therapies such as tyrosine kinase inhibitors. In March 2023, the American Medical Association reported a 2.7% increase in health spending in the United States, reaching $4.3 trillion or $12,914 per capita in 2021. This upward trend in healthcare spending contributes significantly to the growth of the tyrosine kinase inhibitors market.

Product innovation emerges as a prominent trend gaining momentum in the tyrosine kinase inhibitor market, with major companies actively adopting new technologies to maintain their market positions. In October 2021, Novartis AG, a Switzerland-based pharmaceutical corporation, obtained approval from the Food and Drug Administration for asciminib (Scemblix), a drug designed for individuals with chronic myeloid leukemia (Ph+ CML) in the chronic phase. This inhibitor demonstrates precise and potent blocking of BCR-ABL1 by binding to a pocket different from the ATP-binding region of the kinase. It presents the potential for dual inhibition of BCR-ABL1, in combination with ATP-binding TKIs, and the ability to overcome resistance to earlier TKIs.

Major companies in the neoantigens targeted therapies market are strategically forming partnerships to establish robust and comprehensive intellectual property. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. In March 2023, Mithra Pharmaceuticals SA, a Belgian-based biotechnology company, entered into a partnership with BCI Pharma, a France-based pharmaceutical technology company. The collaboration aims to develop novel tyrosine kinase inhibitors, focusing primarily on endometriosis and cancer, including orphan indications such as triple-negative breast cancer (TNBC).

In June 2022, Bristol Myers Squibb, a US-based pharmaceutical company, completed the acquisition of Turning Point Therapeutics Inc. for an undisclosed amount. This strategic move enables Bristol Myers Squibb to expand its leading oncology franchise and fully harness the potential of the precision oncology platform for enhancing standard cancer treatment. Turning Point Therapeutics Inc., a US-based pharmaceutical company, specializes in manufacturing precision medicines for cancer and other diseases, including tyrosine kinase inhibitors.

Major companies operating in the tyrosine kinase inhibitors market report are Pfizer Inc., Johnson And Johnson Private Limited., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Array BioPharma Inc., Glenmark Pharmaceuticals Ltd., Blueprint Medicines Corporation, Loxo Oncology Inc., Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., ArQule Inc.

North America was the largest region in the tyrosine kinase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tyrosine kinase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tyrosine kinase inhibitors market consists of sales of gleevec, dasatinib (Sprycel), nilotinib (Tasigna), erlotinib (Tarceva), crizotinib (Xalkori), and sunitinib (Sutent). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tyrosine Kinase Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tyrosine kinase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tyrosine kinase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tyrosine kinase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: BCR-ABL Tyrosine Kinase Inhibitor; Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors; Other Types
• 2) By Distribution Channel: Hospital Pharmacy; Independent Pharmacies; Online Pharmacies
• 3) By Application: Chronic Myeloid Leukemia (CML); Lung Cancer; Breast Cancer; Renal Cell Cancer; Other Applications
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson Private Limited.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tyrosine Kinase Inhibitors Market Characteristics

3. Tyrosine Kinase Inhibitors Market Trends And Strategies

4. Tyrosine Kinase Inhibitors Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Tyrosine Kinase Inhibitors Market Size and Growth

• 5.1. Global Tyrosine Kinase Inhibitors Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Tyrosine Kinase Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Tyrosine Kinase Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Tyrosine Kinase Inhibitors Market Segmentation

• 6.1. Global Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
• Other Types
• 6.2. Global Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Independent Pharmacies
• Online Pharmacies
• 6.3. Global Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Renal Cell Cancer
• Other Applications

7. Tyrosine Kinase Inhibitors Market Regional And Country Analysis

• 7.1. Global Tyrosine Kinase Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Tyrosine Kinase Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Tyrosine Kinase Inhibitors Market

• 8.1. Asia-Pacific Tyrosine Kinase Inhibitors Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Tyrosine Kinase Inhibitors Market

• 9.1. China Tyrosine Kinase Inhibitors Market Overview
• 9.2. China Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Tyrosine Kinase Inhibitors Market

• 10.1. India Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Tyrosine Kinase Inhibitors Market

• 11.1. Japan Tyrosine Kinase Inhibitors Market Overview
• 11.2. Japan Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Tyrosine Kinase Inhibitors Market

• 12.1. Australia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Tyrosine Kinase Inhibitors Market

• 13.1. Indonesia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Tyrosine Kinase Inhibitors Market

• 14.1. South Korea Tyrosine Kinase Inhibitors Market Overview
• 14.2. South Korea Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Tyrosine Kinase Inhibitors Market

• 15.1. Western Europe Tyrosine Kinase Inhibitors Market Overview
• 15.2. Western Europe Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Tyrosine Kinase Inhibitors Market

• 16.1. UK Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Tyrosine Kinase Inhibitors Market

• 17.1. Germany Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Tyrosine Kinase Inhibitors Market

• 18.1. France Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Tyrosine Kinase Inhibitors Market

• 19.1. Italy Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Tyrosine Kinase Inhibitors Market

• 20.1. Spain Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Tyrosine Kinase Inhibitors Market

• 21.1. Eastern Europe Tyrosine Kinase Inhibitors Market Overview
• 21.2. Eastern Europe Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Tyrosine Kinase Inhibitors Market

• 22.1. Russia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Tyrosine Kinase Inhibitors Market

• 23.1. North America Tyrosine Kinase Inhibitors Market Overview
• 23.2. North America Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Tyrosine Kinase Inhibitors Market

• 24.1. USA Tyrosine Kinase Inhibitors Market Overview
• 24.2. USA Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Tyrosine Kinase Inhibitors Market

• 25.1. Canada Tyrosine Kinase Inhibitors Market Overview
• 25.2. Canada Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Tyrosine Kinase Inhibitors Market

• 26.1. South America Tyrosine Kinase Inhibitors Market Overview
• 26.2. South America Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Tyrosine Kinase Inhibitors Market

• 27.1. Brazil Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Tyrosine Kinase Inhibitors Market

• 28.1. Middle East Tyrosine Kinase Inhibitors Market Overview
• 28.2. Middle East Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Tyrosine Kinase Inhibitors Market

• 29.1. Africa Tyrosine Kinase Inhibitors Market Overview
• 29.2. Africa Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Tyrosine Kinase Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Tyrosine Kinase Inhibitors Market Competitive Landscape
• 30.2. Tyrosine Kinase Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson And Johnson Private Limited.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Tyrosine Kinase Inhibitors Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca Plc.
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. Astellas Pharma Inc.
• 31.12. Eisai Co. Ltd
• 31.13. Incyte Corporation
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Exelixis Inc.

32. Global Tyrosine Kinase Inhibitors Market Competitive Benchmarking

33. Global Tyrosine Kinase Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Tyrosine Kinase Inhibitors Market

35. Tyrosine Kinase Inhibitors Market Future Outlook and Potential Analysis

• 35.1 Tyrosine Kinase Inhibitors Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Tyrosine Kinase Inhibitors Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Tyrosine Kinase Inhibitors Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer